Cargando…

Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma

BACKGROUND: Stratification of tumors is necessary to achieve better clinical outcomes. Hepatocellular carcinoma (HCC) is commonly associated with mutation of the TP53 gene and heterogeneity in immune cell content. However, TP53 mutation-associated immunotype of HCC has not been reported yet. This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Muqi, Wang, Yan, Tang, Weidong, Cui, Xiaohong, Wu, Han, Tang, Yijie, Wang, Peng, Wu, Wei, Zhang, Haijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186599/
https://www.ncbi.nlm.nih.gov/pubmed/32355765
http://dx.doi.org/10.21037/atm.2020.02.98
_version_ 1783526984127610880
author Shi, Muqi
Wang, Yan
Tang, Weidong
Cui, Xiaohong
Wu, Han
Tang, Yijie
Wang, Peng
Wu, Wei
Zhang, Haijian
author_facet Shi, Muqi
Wang, Yan
Tang, Weidong
Cui, Xiaohong
Wu, Han
Tang, Yijie
Wang, Peng
Wu, Wei
Zhang, Haijian
author_sort Shi, Muqi
collection PubMed
description BACKGROUND: Stratification of tumors is necessary to achieve better clinical outcomes. Hepatocellular carcinoma (HCC) is commonly associated with mutation of the TP53 gene and heterogeneity in immune cell content. However, TP53 mutation-associated immunotype of HCC has not been reported yet. This study aimed to identify the TP53 mutation-associated immunotype in HCC. METHODS: The mutation annotation format (MAF) document, mRNA expression data, and clinical data of HCC patients were downloaded from the publicly available The Cancer Genome Atlas (TCGA) data portal. Data from 332 HCC patients were analyzed in this study. Infiltrating immune cells were evaluated by the well-known CIBERSORT method. Additional mutation data of HCC patients were downloaded from the Catalogue of Somatic Mutations in Cancer (COSMIC) database. RESULTS: The TP53 gene harbored the highest frequency of mutations in HCC patients. Consequently, five lethal features, including TP53 mutations, were screened by least absolute shrinkage and selector operation (LASSO)-COX regression, according to TP53 mutations and 22 infiltrating immune cells. Two distinct subgroups of HCC were identified, namely, immunotypes A and B. Furthermore, the expression levels of co-inhibitory immune checkpoints were significantly upregulated, and the gene ontology (GO) terms or pathways to boost immune responses were found to be inhibited in the immunotype B subgroup compared to that in the immunotype A subgroup. Finally, we proved immunotype to be an independent adverse prognostic factor that contributed to improvement in the predictive accuracy of the immunotype-based model and helped in avoiding excessive medical treatment. CONCLUSIONS: Two distinct immunotypes of HCC, in terms of prognosis, phenotype, and function, were identified and the traditional understanding of intratumoralCD8(+) T cells was subverted. Moreover, the identified immunotypes contributed to improving the predictive accuracy of the immunotype-based model and helped in avoiding excessive medical treatment in some HCC patients.
format Online
Article
Text
id pubmed-7186599
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-71865992020-04-30 Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma Shi, Muqi Wang, Yan Tang, Weidong Cui, Xiaohong Wu, Han Tang, Yijie Wang, Peng Wu, Wei Zhang, Haijian Ann Transl Med Original Article BACKGROUND: Stratification of tumors is necessary to achieve better clinical outcomes. Hepatocellular carcinoma (HCC) is commonly associated with mutation of the TP53 gene and heterogeneity in immune cell content. However, TP53 mutation-associated immunotype of HCC has not been reported yet. This study aimed to identify the TP53 mutation-associated immunotype in HCC. METHODS: The mutation annotation format (MAF) document, mRNA expression data, and clinical data of HCC patients were downloaded from the publicly available The Cancer Genome Atlas (TCGA) data portal. Data from 332 HCC patients were analyzed in this study. Infiltrating immune cells were evaluated by the well-known CIBERSORT method. Additional mutation data of HCC patients were downloaded from the Catalogue of Somatic Mutations in Cancer (COSMIC) database. RESULTS: The TP53 gene harbored the highest frequency of mutations in HCC patients. Consequently, five lethal features, including TP53 mutations, were screened by least absolute shrinkage and selector operation (LASSO)-COX regression, according to TP53 mutations and 22 infiltrating immune cells. Two distinct subgroups of HCC were identified, namely, immunotypes A and B. Furthermore, the expression levels of co-inhibitory immune checkpoints were significantly upregulated, and the gene ontology (GO) terms or pathways to boost immune responses were found to be inhibited in the immunotype B subgroup compared to that in the immunotype A subgroup. Finally, we proved immunotype to be an independent adverse prognostic factor that contributed to improvement in the predictive accuracy of the immunotype-based model and helped in avoiding excessive medical treatment. CONCLUSIONS: Two distinct immunotypes of HCC, in terms of prognosis, phenotype, and function, were identified and the traditional understanding of intratumoralCD8(+) T cells was subverted. Moreover, the identified immunotypes contributed to improving the predictive accuracy of the immunotype-based model and helped in avoiding excessive medical treatment in some HCC patients. AME Publishing Company 2020-03 /pmc/articles/PMC7186599/ /pubmed/32355765 http://dx.doi.org/10.21037/atm.2020.02.98 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Shi, Muqi
Wang, Yan
Tang, Weidong
Cui, Xiaohong
Wu, Han
Tang, Yijie
Wang, Peng
Wu, Wei
Zhang, Haijian
Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma
title Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma
title_full Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma
title_fullStr Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma
title_full_unstemmed Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma
title_short Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma
title_sort identification of tp53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186599/
https://www.ncbi.nlm.nih.gov/pubmed/32355765
http://dx.doi.org/10.21037/atm.2020.02.98
work_keys_str_mv AT shimuqi identificationoftp53mutationassociatedimmunotypeandpredictionofsurvivalinpatientswithhepatocellularcarcinoma
AT wangyan identificationoftp53mutationassociatedimmunotypeandpredictionofsurvivalinpatientswithhepatocellularcarcinoma
AT tangweidong identificationoftp53mutationassociatedimmunotypeandpredictionofsurvivalinpatientswithhepatocellularcarcinoma
AT cuixiaohong identificationoftp53mutationassociatedimmunotypeandpredictionofsurvivalinpatientswithhepatocellularcarcinoma
AT wuhan identificationoftp53mutationassociatedimmunotypeandpredictionofsurvivalinpatientswithhepatocellularcarcinoma
AT tangyijie identificationoftp53mutationassociatedimmunotypeandpredictionofsurvivalinpatientswithhepatocellularcarcinoma
AT wangpeng identificationoftp53mutationassociatedimmunotypeandpredictionofsurvivalinpatientswithhepatocellularcarcinoma
AT wuwei identificationoftp53mutationassociatedimmunotypeandpredictionofsurvivalinpatientswithhepatocellularcarcinoma
AT zhanghaijian identificationoftp53mutationassociatedimmunotypeandpredictionofsurvivalinpatientswithhepatocellularcarcinoma